Candel Therapeutics Inc. (CADL)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential
Candel Therapeutics is transitioning from a high-risk clinical-stage biotech to a late-stage oncology company with a BLA-directed lead asset. CAN-2409 has achieved positive Phase III results in localized prostate cancer, with additional promising data in NSCLC and PDAC, supporting a 'pipeline in a product' thesis. CADL's valuation appears overly pessimistic given its regulatory catalysts, improved financial runway into Q1 2028, and multiple clinical-stage assets.
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BG Bart Gancher Intech Investment Management LLC | 11,787 | $66,596.55 | $115,456.02 | $48,859.47 | 73.37% |
 Point72 Asset Management LP Point72 Asset Management LP | 107,211 | $525,334 | $1.03M | $507,107.93 | 96.53% |
 Joseph Castro Nuveen LLC | 93,158 | $474,970.51 | $897,111.54 | $422,141.03 | 88.88% |
 Alexander Eichhorn Tanager Wealth Management LLP | 198,175 | $1M | $1.91M | $905,597.99 | 90.3% |
 Li Peng China Universal Asset Management Co. Ltd. | 12,998 | $70,399.7 | $124,845.79 | $54,446.09 | 77.34% |
Candel Therapeutics Inc. (CADL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Candel Therapeutics Inc. ever had a stock split?
Candel Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Paul-Peter Tak CEO | NASDAQ (NMS) Exchange | 137404109 CUSIP |
| US Country | 55 Employees | - Last Dividend | - Last Split | 27 Jul 2021 IPO Date |
Overview
Candel Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company rooted in the discovery and development of novel immunotherapies aimed at treating cancer patients. With a focus on leveraging innovative technologies and scientific advances, Candel Therapeutics is committed to achieving breakthroughs in cancer treatment. Since its inception in 2003 under the name Advantagene, Inc., the company has undergone a significant evolution, culminating in a name change to Candel Therapeutics, Inc. in November 2020. Headquartered in Needham, Massachusetts, the organization continues to push the boundaries of cancer therapy with its diverse pipeline of drug candidates and proprietary discovery platforms.
Products and Services
- CAN-2409
- CAN-3110
- enLIGHTEN Discovery Platform
